OKUR
NASDAQOnKure Therapeutics Inc.
$4.84-0.07 (-1.33%)
News25/Ratings3
Price$4.84-0.17 (-3.39%)
01:30 PM06:15 PM
News · 26 weeks37+117%
2025-10-262026-04-19
Mix2290d
- Insider9(41%)
- Other6(27%)
- SEC Filings6(27%)
- Offering1(5%)
Latest news
25 items- SECSEC Form DEFA14A filed by OnKure Therapeutics Inc.DEFA14A - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form DEF 14A filed by OnKure Therapeutics Inc.DEF 14A - OnKure Therapeutics, Inc. (0001637715) (Filer)
- INSIDERSEC Form 3 filed by new insider Ai Biotechnology Llc3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- INSIDERSEC Form 4 filed by Saccomano Nicholas A4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Leverone Jason A.4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Hartley Dylan4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Agresta Samuel4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Ratcliffe Liam4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ratcliffe Liam3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- PROnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of a
- INSIDERSEC Form 4 filed by Saccomano Nicholas A4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Leverone Jason A.4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECSEC Form S-8 filed by OnKure Therapeutics Inc.S-8 - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form 10-K filed by OnKure Therapeutics Inc.10-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
- INSIDERDirector Mathers Edward T was granted 3,911 shares, increasing direct ownership by 34% to 15,310 units (SEC Form 4)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERDirector Manke Isaac was granted 5,258 shares, increasing direct ownership by 34% to 20,583 units (SEC Form 4)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERPresident and CEO Saccomano Nicholas A sold $258 worth of shares (87 units at $2.97), decreasing direct ownership by 1% to 7,419 units (SEC Form 4)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)